

April 18, 2011

Company Name: JAPAN TOBACCO INC.
Representative: Hiroshi Kimura, President, Chief Executive Officer and Representative Director
(Stock Code: 2914; Stock Exchanges: Tokyo/Osaka/Nagoya First Section, Fukuoka and Sapporo)
Contact: Media and Investor Relations Division
Tel: +81-3-3582-3111

Notice Concerning Amendments to Earnings Forecasts of JT's Subsidiary

Japan Tobacco Inc. (JT) today announced that Torii Pharmaceutical Co., Ltd., a consolidated subsidiary of JT, amended the full-year earnings forecasts for the March 2011 term (April 1, 2010 through March 31, 2011) as the attached sheet.

The effects of this amendment on JT's consolidated financial results will be immaterial.

(Attachment)

Attached sheet: "Torii Amends Earnings Forecasts for March 2011 Term" (a material released by Torii Pharmaceutical Co., Ltd. as of April 18, 2011)

* * * * *

April 18, 2011

Torii Pharmaceutical Co., Ltd.

Torii Amends Earnings Forecasts for March 2011 Term

In accord with recent business performance trend, etc., Torii Pharmaceutical Co., Ltd. ("Torii") announced today that it has amended, as below, its earnings forecasts for the fiscal year ending March 31, 2011, announced on February 3, 2011.

1. Amendments of Full-Year Earnings Forecasts for March 2011 Term (April 1, 2010 through March 31, 2011)

(Millions of yen)

	Net sales (Millions of yen)	Operating income (Millions of yen)	Ordinary income (Millions of yen)	Net income (Millions of yen)	Net income per share (Yen)
Previous forecasts (A)	44,200	1,200	1,400	700	24.73
New forecasts (B)	45,300	1,800	2,000	900	31.80
Amounts changed (B-A)	1,100	600	600	200	
Rate of change (%)	2.5	50.0	42.9	28.6	
(Reference) Previous fiscal year actual results (March 2010 term)	42,416	6,125	6,371	3,642	128.69

2. Reasons for Amendments

Net sales is expected to be higher than the previous forecasts figures mainly because of the growth in sales of REMITCH CAPSULES, an oral antipruritus drug for hemodialysis patients, and Truvada Tablets, an anti-HIV drug. Therefore operating income, ordinary income and net income are expected to be higher than the previous forecasts figures.

* The above-mentioned earnings forecasts are based on information available to the Company as the date of announcement of this material. Actual business results may differ from the forecasts figures herein.

* * * * *